4.
纳入的非小细胞肺癌KRAS突变研究
Eligible studies for KRAS mutation of NSCLC
| KRAS mutation | Pairs | Primary NSCLC | Metastases | Inconsistency | |||||
| n | Percent | n | Percent | n | Percent | ||||
| Badalian G[28] | 11 | 3 | 27.27% | 3 | 27.27% | 4 | 36.36% | ||
| Cortot AB[18] | 21 | 3 | 14.29% | 4 | 19.05% | 6 | 28.57% | ||
| Kalikaki A[19] | 25 | 5 | 20.00% | 5 | 20.00% | 6 | 24.00% | ||
| Schmid K[22] | 96 | 28 | 29.17% | 20 | 20.83% | 25 | 26.04% | ||
| Monaco SE[25] | 40 | 11 | 27.50% | 4 | 10.00% | 9 | 22.50% | ||
| Sum | 193 | 50 | 25.91% | 36 | 18.65% | 50 | 25.91% | ||